Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 63, Issue 6, 2007, Pages 571-581

  Dorani, Hassan ^a   Schützer, Kajs Marie ^a   Sarich, Troy C ^b,c   Wall, Ulrika ^a   Logren, Ulrika ^a   Ohlsson, Lis ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibiotic interactions; Melagatran; Oral direct thrombin inhibitors; P glycoprotein pump (p GP); Ximelagatran

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMAX; AZITHROMYCIN; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CYTOCHROME P450; DOXYCYCLINE; GLYCOPROTEIN P; MELAGATRAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; THROMBIN;

EID: 34247637272     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0292-6     Document Type: Article

References (31)

1. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Patridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, SPORTIF Executive Steering Committee For The SPORTIF V Investigators (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293(6):690-698
2. Balayssac D, Authier N, Cayre A, Coudore F (2005) Does inhibition of p-glycoprotein lead to drug-drug interactions? Toxicol Lett 156:319-329
3. Benet LZ, Cummins CL, Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9
4. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777
5. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1:2490-2496
6. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, METHRO III Study Group (2003) Direct thrombin inhibitor melagatran followed by oral ximegalatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89(2):288-296
7. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31:294-305
8. Eriksson UG, Dorani H, Karlsson J, Fritsch H, Hoffmann KJ, Olsson L, Sarich TC, Wall U, Schutzer KM (2006) Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein- mediated excretion. Drug Metab Dispos 34:775-782
9. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS, THRIVE Treatment Study Investigators (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293(6):681-689
10. Fischer V, Einolf HJ, Cohen D (2005) Efflux transporters and their relevance. Mini-reviews in medicinal chemistry 5:183-195
11. Francis CW (2004) Ximelagatran: a new oral anticoagulant. Best Pract Res Clin Haematol 17:139-152
12. Gustafsson D (2003) Oral direct thrombin inhibitors in clinical development. J Intern Med 254:322-334
13. Gustafsson D, Elg M (2003) The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109(Suppl 1):S9-S15
14. Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260-277
15. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson BA (2002) Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 766:47-55
16. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Öhrman I, Persson BA (2003) Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B 783:335-347
17. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351-370
18. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33
19. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461
20. Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698
21. Pachot JI, Botham RP, Haegele KD, Hwang K (2003) Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci 6:1-12
22. Sarich TC, Johansson S, Schutzer KM, Wall U, Kessler E, Teng R, Eriksson UG (2004) The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 44:388-393
23. Sarich TC, Schutzer KM, Dorani H, Wall U, Kalies I, Ohlsson L, Eriksson UG (2004) No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 44:928-934
24. Sarich TC, Schutzer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG (2004) No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 44:935-941
25. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349:1713-1721
26. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:RA5-RA14
27. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294
28. Teng R, Sarich TC, Eriksson UG, Hamer JE, Gillette S, Schutzer KM, Carlson GF Jr, Kowey PR (2004) A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 44:1063-1071
29. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H (2002) Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107:93-99
30. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789-797
31. Wolzt M, Sarich TS, Eriksson UG (2005) Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. Semin Vasc Med 5:254-258